228 related articles for article (PubMed ID: 26865042)
1. Lack of association between polymorphisms in the CYP1A2 gene and risk of cancer: evidence from meta-analyses.
Vukovic V; Ianuale C; Leoncini E; Pastorino R; Gualano MR; Amore R; Boccia S
BMC Cancer; 2016 Feb; 16():83. PubMed ID: 26865042
[TBL] [Abstract][Full Text] [Related]
2. Current evidence on the relationship between three polymorphisms in the CYP1A2 gene and the risk of cancer.
Zhenzhen L; Xianghua L; Ning S; Zhan G; Chuanchuan R; Jie L
Eur J Cancer Prev; 2013 Nov; 22(6):607-19. PubMed ID: 23462460
[TBL] [Abstract][Full Text] [Related]
3. CYP1A2 rs762551 polymorphism contributes to risk of lung cancer: a meta-analysis.
Ma Z; Guo W; Gong T; Niu HJ; Wang RW; Jiang YG
Tumour Biol; 2014 Mar; 35(3):2253-7. PubMed ID: 24293373
[TBL] [Abstract][Full Text] [Related]
4. Association between the CYP1A2 rs762551 Polymorphism and Bladder Cancer Susceptibility: a Meta-Analysis Based on Case-Control Studies.
Zeng Y; Jiang HY; Wei L; Xu WD; Wang YJ; Wang YD; Liu C
Asian Pac J Cancer Prev; 2015; 16(16):7249-54. PubMed ID: 26514519
[TBL] [Abstract][Full Text] [Related]
5. CYP1A2 rs762551 polymorphism contributes to cancer susceptibility: a meta-analysis from 19 case-control studies.
Wang H; Zhang Z; Han S; Lu Y; Feng F; Yuan J
BMC Cancer; 2012 Nov; 12():528. PubMed ID: 23157985
[TBL] [Abstract][Full Text] [Related]
6. Association between the CYP1A2 polymorphisms and risk of cancer: a meta-analysis.
Sun WX; Chen YH; Liu ZZ; Xie JJ; Wang W; Du YP; Chen Y; Shen XL; He XF; Wu LX; Wei W; Zhang L
Mol Genet Genomics; 2015 Apr; 290(2):709-25. PubMed ID: 25472037
[TBL] [Abstract][Full Text] [Related]
7. Four polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene and lung cancer risk: a meta-analysis.
Bu ZB; Ye M; Cheng Y; Wu WZ
Asian Pac J Cancer Prev; 2014; 15(14):5673-9. PubMed ID: 25081684
[TBL] [Abstract][Full Text] [Related]
8. Role of CYP1A2 1F polymorphism in cancer risk: evidence from a meta-analysis of 46 case-control studies.
Tian Z; Li YL; Zhao L; Zhang CL
Gene; 2013 Jul; 524(2):168-74. PubMed ID: 23628800
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of correlation between the CYP1A2 -3860 G > A polymorphism and lung cancer risk.
Ren J; He BZ; Zhang TS; Lu SP; Yan T
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323197
[TBL] [Abstract][Full Text] [Related]
11. Association between CYP1A2 and CYP1B1 polymorphisms and colorectal cancer risk: a meta-analysis.
He XF; Wei J; Liu ZZ; Xie JJ; Wang W; Du YP; Chen Y; Si HQ; Liu Q; Wu LX; Wei W
PLoS One; 2014; 9(8):e100487. PubMed ID: 25115775
[TBL] [Abstract][Full Text] [Related]
12. Association of CYP19A1 and CYP1A2 genetic polymorphisms with type 2 diabetes mellitus risk in the Chinese Han population.
Yang Y; Wang P
Lipids Health Dis; 2020 Aug; 19(1):187. PubMed ID: 32814585
[TBL] [Abstract][Full Text] [Related]
13. quantitative assessment of the influence of cytochrome P450 1A2 gene polymorphism and colorectal cancer risk.
Zhao Y; Chen ZX; Rewuti A; Ma YS; Wang XF; Xia Q; Fu D; Han YS
PLoS One; 2013; 8(8):e71481. PubMed ID: 23951174
[TBL] [Abstract][Full Text] [Related]
14. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
[TBL] [Abstract][Full Text] [Related]
15. Gender and ethnicity modify the association between the CYP1A2 rs762551 polymorphism and habitual coffee intake: evidence from a meta-analysis.
Denden S; Bouden B; Haj Khelil A; Ben Chibani J; Hamdaoui MH
Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173183
[TBL] [Abstract][Full Text] [Related]
16. Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: a meta-analysis involving 17,600 subjects.
Qiu LX; Yao L; Mao C; Yu KD; Zhan P; Chen B; Yuan H; Zhang J; Xue K; Hu XC
Breast Cancer Res Treat; 2010 Jul; 122(2):521-5. PubMed ID: 20054636
[TBL] [Abstract][Full Text] [Related]
17. CYP1A2 rs762551 polymorphism and risk for amyotrophic lateral sclerosis.
Siokas V; Karampinis E; Aloizou AM; Mentis AA; Liakos P; Papadimitriou D; Liampas I; Nasios G; Bogdanos DP; Hadjigeorgiou GM; Dardiotis E
Neurol Sci; 2021 Jan; 42(1):175-182. PubMed ID: 32592103
[TBL] [Abstract][Full Text] [Related]
18. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.
Kim IY; O'Reilly ÉJ; Hughes KC; Gao X; Schwarzschild MA; McCullough ML; Hannan MT; Betensky RA; Ascherio A
Mov Disord; 2018 Mar; 33(3):414-420. PubMed ID: 29318639
[TBL] [Abstract][Full Text] [Related]
19. CYP1A2 polymorphisms, occupational and environmental exposures and risk of bladder cancer.
Pavanello S; Mastrangelo G; Placidi D; Campagna M; Pulliero A; Carta A; Arici C; Porru S
Eur J Epidemiol; 2010 Jul; 25(7):491-500. PubMed ID: 20559687
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the CYP1A2 -163C>A polymorphism and lung cancer risk.
Deng SQ; Zeng XT; Wang Y; Ke Q; Xu QL
Asian Pac J Cancer Prev; 2013; 14(5):3155-8. PubMed ID: 23803095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
